



2027

HOSPITAL RECOGNITION CRITERIA

Based on 2026 data

Target Ablation Recognition

Composite score 75% or greater on all measures.

Rationale: Ablation is a Class I recommendation for first line therapy for new onset atrial fibrillation. Optimal medical management remains an essential component of the care of the AFib patient receiving ablation. Target ablation recognition is designed to highlight the hospitals that provide optimal care to the ablation population.

Target Ablation is a composite score of the achievement measures isolated to the patients that receive ablation. A composite score of 75% is the criteria for recognition in this category. Recognition will commence in 2026 based on 2025 data.



AHAAF71: ACEI/ARB or ARNI Prescribed Prior to Discharge for Ablation (when LVEF \leq 40)

AHAAF72: Beta Blocker Prescribed Prior to Discharge for Ablation (when LVEF \leq 40)

AHAAF73: CHA2DS2-VASc Risk Score Documented Prior to Discharge for Ablation

AHAAF74: FDA approved Anticoagulation Prescribed Prior to Discharge for Ablation

AHAAF75: Statin at discharge for Ablation patients with CAD, CVA/TIA, PVD, or Diabetes

AHAAF76: Ablation Composite Score

AHAAF78: Defect-Free Care for Ablation